{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:52Z","timestamp":1794097552660,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00125-011-2232-3","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T13:11:29Z","timestamp":1310130689000},"page":"2745-2754","source":"Crossref","is-referenced-by-count":180,"title":["Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis"],"prefix":"10.1007","volume":"54","author":[{"given":"A. E.","family":"Hogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Corrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gaoatswe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Moynagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,9]]},"reference":[{"key":"2232_CR1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829\u2013835","journal-title":"J Am Acad Dermatol"},{"key":"2232_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","volume":"157","author":"P Gisondi","year":"2007","unstructured":"Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case\u2013control study. Br J Dermatol 157:68\u201373","journal-title":"Br J Dermatol"},{"key":"2232_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","volume":"298","author":"DM Sommer","year":"2006","unstructured":"Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298:321\u2013328","journal-title":"Arch Dermatol Res"},{"key":"2232_CR4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archdermatol.2009.48","volume":"145","author":"AA Qureshi","year":"2009","unstructured":"Qureshi AA, Choi HK, Setty AR, Curhan GC (2009) Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145:379\u2013382","journal-title":"Arch Dermatol"},{"key":"2232_CR5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI200525102","volume":"115","author":"KE Wellen","year":"2005","unstructured":"Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111\u20131119","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"2232_CR6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2133.2008.08780.x","volume":"159","author":"F Spah","year":"2008","unstructured":"Spah F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10\u201317","journal-title":"Br J Dermatol"},{"key":"2232_CR7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/B:EJEP.0000020447.59150.f9","volume":"19","author":"L Mallbris","year":"2004","unstructured":"Mallbris L, Akre O, Granath F et al (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19:225\u2013230","journal-title":"Eur J Epidemiol"},{"key":"2232_CR8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735\u20131741","journal-title":"JAMA"},{"key":"2232_CR9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/archinte.162.16.1867","volume":"162","author":"PW Wilson","year":"2002","unstructured":"Wilson PW, D\u2019Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867\u20131872","journal-title":"Arch Intern Med"},{"key":"2232_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/oby.2008.565","volume":"17","author":"LA Lynch","year":"2009","unstructured":"Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C, O'Shea DB (2009) Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 17:601\u2013605","journal-title":"Obesity (Silver Spring)"},{"key":"2232_CR11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/eji.200939349","volume":"39","author":"L Lynch","year":"2009","unstructured":"Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C (2009) Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39:1893\u20131901","journal-title":"Eur J Immunol"},{"key":"2232_CR12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/eji.200737838","volume":"38","author":"TY Liu","year":"2008","unstructured":"Liu TY, Uemura Y, Suzuki M et al (2008) Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 38:1012\u20131023","journal-title":"Eur J Immunol"},{"key":"2232_CR13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1468-3083.2009.03292.x","volume":"23","author":"S Peternel","year":"2009","unstructured":"Peternel S, Kastelan M (2009) Immunopathogenesis of psoriasis: focus on natural killer T cells. J Eur Acad Dermatol Venereol 23:1123\u20131127","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2232_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxp104","volume":"22","author":"M Taniguchi","year":"2010","unstructured":"Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H (2010) The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 22:1\u20136","journal-title":"Int Immunol"},{"key":"2232_CR15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.2006.08.5787","volume":"25","author":"JW Molling","year":"2007","unstructured":"Molling JW, Langius JA, Langendijk JA et al (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25:862\u2013868","journal-title":"J Clin Oncol"},{"key":"2232_CR16","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/ard.2009.125849","volume":"69","author":"SJ Tudhope","year":"2010","unstructured":"Tudhope SJ, von Delwig A, Falconer J et al (2010) Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Ann Rheum Dis 69:1873\u20131879","journal-title":"Ann Rheum Dis"},{"key":"2232_CR17","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/art.22714","volume":"56","author":"S Kaieda","year":"2007","unstructured":"Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S (2007) Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 56:1836\u20131845","journal-title":"Arthritis Rheum"},{"key":"2232_CR18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.diabet.2008.09.001","volume":"34","author":"J Girard","year":"2008","unstructured":"Girard J (2008) The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: concept and physiological functions. Diabetes Metab 34:550\u2013559","journal-title":"Diabetes Metab"},{"key":"2232_CR19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409\u20131439","journal-title":"Physiol Rev"},{"key":"2232_CR20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1210\/en.2007-1137","volume":"149","author":"I Hadjiyanni","year":"2008","unstructured":"Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ (2008) Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338\u20131349","journal-title":"Endocrinology"},{"key":"2232_CR21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"I Hadjiyanni","year":"2010","unstructured":"Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ (2010) Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53:730\u2013740","journal-title":"Diabetologia"},{"key":"2232_CR22","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","volume":"67","author":"N Marx","year":"2010","unstructured":"Marx N, Burgmaier M, Heinz P et al (2010) Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67:3549\u20133555","journal-title":"Cell Mol Life Sci"},{"key":"2232_CR23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/db08-1101","volume":"58","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58:641\u2013651","journal-title":"Diabetes"},{"key":"2232_CR24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","volume":"20","author":"JL Matsuda","year":"2008","unstructured":"Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-restricted iNKT cells, the \u2018Swiss-Army knife\u2019 of the immune system. Curr Opin Immunol 20:358\u2013368","journal-title":"Curr Opin Immunol"},{"key":"2232_CR25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00403-002-0349-4","volume":"294","author":"AL Cameron","year":"2002","unstructured":"Cameron AL, Kirby B, Fei W, Griffiths CE (2002) Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 294:363\u2013369","journal-title":"Arch Dermatol Res"},{"key":"2232_CR26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2133.2003.05319.x","volume":"149","author":"AL Cameron","year":"2003","unstructured":"Cameron AL, Kirby B, Griffiths CE (2003) Circulating natural killer cells in psoriasis. Br J Dermatol 149:160\u2013164","journal-title":"Br J Dermatol"},{"key":"2232_CR27","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.4049\/jimmunol.165.7.4076","volume":"165","author":"B Bonish","year":"2000","unstructured":"Bonish B, Jullien D, Dutronc Y et al (2000) Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 165:4076\u20134085","journal-title":"J Immunol"},{"key":"2232_CR28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0923-1811(00)00120-1","volume":"24","author":"BJ Nickoloff","year":"2000","unstructured":"Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24:212\u2013225","journal-title":"J Dermatol Sci"},{"key":"2232_CR29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1172\/JCI0215832","volume":"110","author":"PT Lee","year":"2002","unstructured":"Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A (2002) Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110:793\u2013800","journal-title":"J Clin Invest"},{"key":"2232_CR30","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db10-1338","volume":"60","author":"J Shirakawa","year":"2011","unstructured":"Shirakawa J, Fujii H, Ohnuma K et al (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60:1246\u20131257","journal-title":"Diabetes"},{"key":"2232_CR31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.amjmed.2010.11.004","volume":"124","author":"R Chilton","year":"2011","unstructured":"Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M (2011) Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 124:S35\u2013S53","journal-title":"Am J Med"},{"key":"2232_CR32","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962\u2013965","journal-title":"Circulation"},{"key":"2232_CR33","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340\u20132350","journal-title":"Circulation"},{"key":"2232_CR34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","volume":"27","author":"JJ Holst","year":"2011","unstructured":"Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27:547\u2013558","journal-title":"Curr Med Res Opin"},{"key":"2232_CR35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2337\/db07-1162","volume":"57","author":"S Lerche","year":"2008","unstructured":"Lerche S, Brock B, Rungby J et al (2008) Glucagon-like peptide-1 inhibits blood\u2013brain glucose transfer in humans. Diabetes 57:325\u2013331","journal-title":"Diabetes"},{"key":"2232_CR36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2009.12.023","volume":"630","author":"PL Mcclean","year":"2009","unstructured":"Mcclean PL, Gault VA, Harriott P, H\u00f6lscher C (2009) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer\u2019s disease. Eur J Pharmacol 630:158\u2013162","journal-title":"Eur J Pharmacol"},{"key":"2232_CR37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","volume":"54","author":"R Kodera","year":"2011","unstructured":"Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965\u2013978","journal-title":"Diabetologia"},{"key":"2232_CR38","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-010-1831-8","volume":"53","author":"Y Hattori","year":"2010","unstructured":"Hattori Y, Jojima T, Tomizawa A et al (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53:2256\u20132263","journal-title":"Diabetologia"},{"key":"2232_CR39","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","volume":"57","author":"WL Suarez-Pinzon","year":"2008","unstructured":"Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281\u20133288","journal-title":"Diabetes"},{"key":"2232_CR40","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s00125-007-0737-6","volume":"50","author":"J Zhang","year":"2007","unstructured":"Zhang J, Tokui Y, Yamagata K et al (2007) Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50:1900\u20131909","journal-title":"Diabetologia"},{"key":"2232_CR41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","volume":"1150","author":"S Xue","year":"2008","unstructured":"Xue S, Wasserfall CH, Parker M et al (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150:152\u2013156","journal-title":"Ann N Y Acad Sci"},{"key":"2232_CR42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diabetes.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126\u20131131","journal-title":"Diabetes"},{"key":"2232_CR43","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","volume":"53","author":"CF Deacon","year":"2004","unstructured":"Deacon CF (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181\u20132189","journal-title":"Diabetes"},{"key":"2232_CR44","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.4049\/jimmunol.1002739","volume":"186","author":"M Mellett","year":"2011","unstructured":"Mellett M, Atzei P, Jackson R, O\u2019Neill LA, Moynagh PN (2011) Mal mediates TLR-induced activation of CREB and expression of IL-10. J Immunol 186:4925\u20134935","journal-title":"J Immunol"},{"key":"2232_CR45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jnutbio.2004.02.003","volume":"15","author":"O Lamas","year":"2004","unstructured":"Lamas O, Martinez JA, Marti A (2004) Energy restriction restores the impaired immune response in overweight (cafeteria) rats. J Nutr Biochem 15:418\u2013425","journal-title":"J Nutr Biochem"},{"key":"2232_CR46","first-page":"631","volume":"17","author":"S Tanaka","year":"1993","unstructured":"Tanaka S, Inoue S, Isoda F et al (1993) Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord 17:631\u2013636","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2232_CR47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11695-010-0250-8","volume":"21","author":"CM Moulin","year":"2011","unstructured":"Moulin CM, Marguti I, Peron JPS, Halpern A, Rizzo LV (2011) Bariatric surgery reverses natural killer (NK) cell activity and NK-related cytokine synthesis impairment induced by morbid obesity. Obes Surg 21:112\u2013118","journal-title":"Obes Surg"},{"key":"2232_CR48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jaad.2010.01.001","volume":"65","author":"EW Hossler","year":"2011","unstructured":"Hossler EW, Maroon MS, Mowad CM (2011) Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 65:198\u2013200","journal-title":"J Am Acad Dermatol"},{"key":"2232_CR49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.numecd.2008.07.004","volume":"18","author":"G Mingrone","year":"2008","unstructured":"Mingrone G (2008) Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis 18:574\u2013579","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00125-011-2232-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T16:59:08Z","timestamp":1560358748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-011-2232-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,9]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s00125-011-2232-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,9]]}}}